Granules India Limited (GRANULES) — Financial Results

Granules India reported FY26 revenue of ₹53,656 crores, up 20% YoY, driven by complex generics and CDMO expansion, with gross margin expanding 355 bps to 65% and EBITDA rising 25% to ₹11,851 crores. PAT grew 19% to ₹5,950 crores, while net debt fell to ₹4,021 crores (net debt/EBITDA ratio of 0.34x). Capex stood at ₹5,547 crores in FY26, with FY27 plans including ₹600 crores for a new API facility, IT infrastructure, and a US distribution center. The company achieved ESG milestones, including EcoVadis Gold and CDP A ratings, and zero waste to landfill certification. Management highlighted FDA readiness, scaling CDMO revenue, and margin resilience near 64-65% gross and 24-25% EBITDA, supported by new peptide capacity in Zurich and India, customer diversification across pharma, biotech, and cosmetics, and a $41 billion combined TAM in ADHD and oncology. No revenue or market share was disclosed for controlled substances like Vyvanse, though pipeline progress and first-to-file opportunities were emphasized.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GRANULES ✨ Ask AI About This